Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells $226,737.42 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total value of $226,737.42. Following the transaction, the senior vice president directly owned 213,476 shares of the company’s stock, valued at approximately $3,635,496.28. This represents a 5.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Theravance Biopharma Stock Performance

Shares of TBPH stock traded up $0.01 on Thursday, hitting $17.04. The company had a trading volume of 306,932 shares, compared to its average volume of 556,140. The stock’s 50-day moving average is $16.96 and its two-hundred day moving average is $16.41. The firm has a market cap of $884.70 million, a P/E ratio of 16.87 and a beta of 0.25. Theravance Biopharma, Inc. has a twelve month low of $13.08 and a twelve month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The firm had revenue of $20.73 million for the quarter, compared to analyst estimates of $22.49 million. Equities research analysts predict that Theravance Biopharma, Inc. will post 1.56 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TBPH. Pacer Advisors Inc. bought a new stake in Theravance Biopharma in the fourth quarter valued at $6,342,000. Wedge Capital Management L L P NC acquired a new stake in shares of Theravance Biopharma in the 2nd quarter valued at about $2,190,000. Renaissance Technologies LLC bought a new stake in Theravance Biopharma in the 1st quarter valued at about $2,076,000. Dimensional Fund Advisors LP increased its position in Theravance Biopharma by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock valued at $15,960,000 after buying an additional 124,658 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new position in Theravance Biopharma during the 1st quarter worth approximately $1,672,000. 99.10% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on TBPH shares. HC Wainwright lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and boosted their target price for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. BTIG Research downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 7th. Finally, JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Eight analysts have rated the stock with a Hold rating, According to MarketBeat.com, Theravance Biopharma presently has an average rating of “Hold” and a consensus price target of $19.40.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.